Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome

Journal of the American Society of Nephrology

Volumn 26, Issue 12, 2015, Pages 3009-3019

  Kerlin, Bryce A ^a,b   Waller, Amanda P ^a   Sharma, Ruchika ^a,b   Chanley, Melinda A ^a   Nieman, Marvin T ^c   Smoyer, William E ^a,d  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PUROMYCIN AMINONUCLEOSIDE; SERUM ALBUMIN; THROMBIN; ANTITHROMBIN; BIOLOGICAL MARKER; FIBRINOGEN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; EX VIVO STUDY; HYPERCOAGULABILITY; HYPOALBUMINEMIA; IN VIVO STUDY; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RISK ASSESSMENT; THROMBOELASTOGRAPHY; THROMBOSIS; ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD COAGULATION DISORDERS; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; ELASTICITY; HEMOSTASIS; MALE; METABOLISM; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; URINE; WISTAR RAT;

ANIMALS; ANTITHROMBINS; BIOMARKERS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; DISEASE MODELS, ANIMAL; DOXORUBICIN; ELASTICITY; FIBRINOGEN; HEMOSTASIS; HYPOALBUMINEMIA; MALE; NEPHROTIC SYNDROME; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, WISTAR; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; THROMBIN; THROMBOSIS;

EID: 84958232352     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014111097     Document Type: Article

References (61)

1. Eddy AA, Symons JM: Nephrotic syndrome in childhood. Lancet 362: 629-639, 2003
2. Orth SR, Ritz E: The nephrotic syndrome. N Engl J Med 338: 1202-1211, 1998
3. Kerlin BA, Ayoob R, SmoyerWE: Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 7: 513-520, 2012
4. Loscalzo J: Venous thrombosis in the nephrotic syndrome. N Engl J Med 368: 956-958, 2013
5. Schlegel N: Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 23: 271-280, 1997
6. Singhal R, Brimble KS: Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res 118: 397-407, 2006
7. Kerlin BA, Haworth K, Smoyer WE: Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol 29: 989-997, 2014
8. Christiansen CF, Schmidt M, Lamberg AL, Horváth-Puhó E, Baron JA, Jespersen B, Sørensen HT: Kidney disease and risk of venous thromboembolism: A nationwide population-based case-control study. J Thromb Haemost 12: 1449-1454, 2014
9. ISTH Steering Committee for World Thrombosis Day: Thrombosis: A major contributor to the global disease burden. J Thromb Haemost 12: 1580-1590, 2014
10. Glassock RJ: Prophylactic anticoagulation in nephrotic syndrome: A clinical conundrum. J Am Soc Nephrol 18: 2221-2225, 2007
11. Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH: Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 85: 1412-1420, 2014
12. Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathicmembranous nephropathy. Kidney Int 45: 578-585, 1994
13. Kumar S, Chapagain A, Nitsch D, Yaqoob MM: Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: An observational study. BMC Nephrol 13: 107, 2012
14. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN: Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43-51, 2012
15. Bellomo R, Atkins RC:Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted? Nephron 63: 249-254, 1993
16. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN: Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 81: 190-195, 2012
17. Kerlin BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C,Mahan JD, Smoyer WE: Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 155: 105-110, 2009
18. Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J: High absolute risks and predictors of venous and arterial thromboembolic events inpatientswith nephrotic syndrome: Results from a large retrospective cohort study. Circulation 117: 224-230, 2008
19. Cruz C, Juárez-Nicolás F, Tapia E, Correa-Rotter R, Pedraza-Chaverrí J: Abnormalities of coagulation in experimental nephrotic syndrome. Nephron 68: 489-496, 1994
20. Poggi A, Kornblihtt L, Delaini F, Colombo T,Mussoni L, Reyers I, Donati MB: Delayed hypercoagulability after a single dose of adriamycin to normal rats. Thromb Res 16: 639-650, 1979
21. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, Krofft RD, Logar CM, Marshall CB, Ohse T, Shankland SJ: Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 296: F213-F229, 2009
22. Morioka Y, Koike H, Ikezumi Y, Ito Y, Oyanagi A, Gejyo F, Shimizu F, Kawachi H: Podocyte injuries exacerbate mesangial proliferative glomerulonephritis. Kidney Int 60: 2192-2204, 2001
23. Hjalmarsson C, Ohlson M, Haraldsson B: Puromycin aminonucleoside damages the glomerular size barrier with minimal effects on charge density. Am J Physiol Renal Physiol 281: F503-F512, 2001
24. Ay L, Hoellerl F, Ay C, Brix JM, Koder S, Schernthaner GH, Pabinger I, Schernthaner G: Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. Eur J Clin Invest 42: 470-477, 2012
25. BesserM, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T: High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 6: 1720-1725, 2008
26. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296: 397-402, 2006
27. Machlus KR, Lin FC, Wolberg AS: Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood 118: 3960-3968, 2011
28. Mahmoodi BK, Mulder AB, Waanders F, Spronk HM, Mulder R, Slagman MC, Vogt L,Navis G, Ten Cate H, Kluin-NelemansHC, LavermanGD: The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. J Thromb Haemost 9: 2416-2423, 2011
29. SanchezC, PoggiM,Morange PE,Defoort C,Martin JC, TanguyS,Dutour A, GrinoM,AlessiMC: Dietmodulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status. Arterioscler Thromb Vasc Biol 32: 2394-2404, 2012
30. van Geffen M, van HeerdeWL: Global haemostasis assays, from bench to bedside. Thromb Res 129: 681-687, 2012
31. Donahue SM, Brooks M, Otto CM: Examination of hemostatic parameters to detect hypercoagulability in dogs with severe protein-losing nephropathy. J Vet Emerg Crit Care (San Antonio) 21: 346-355, 2011
32. Lennon EM, Hanel RM, Walker JM, Vaden SL: Hypercoagulability in dogs with protein-losing nephropathy as assessed by thromboelastography. J Vet Intern Med 27: 462-468, 2013
33. Papa ML, Capasso F, Pudore L, Torre S, Mango S, Russo V, Delrio P, Palaia R, Ruffolo F, d'EufemiaMD, De Lucia D, NapolitanoM, Di Micco P, Parisi V: Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer. Exp Oncol 29: 111-115, 2007
34. Rossetto V, Spiezia L, Senzolo M, Rodriguez-Castro KI, Maggiolo S, Simioni P: Whole blood rotation thromboelastometry (ROTEM) profiles in subjects with non-neoplastic portal vein thrombosis. Thromb Res 132: e131-e134, 2013
35. Taura P, Rivas E, Martinez-Palli G, Blasi A, Holguera JC, Balust J, Delgado S, Lacy AM: Clinical markers of the hypercoagulable state by rotational thrombelastometry in obese patients submitted to bariatric surgery. Surg Endosc 28: 543-551, 2014
36. Ko RH, Ji L, Young G: A novel approach for detecting hypercoagulability utilizing thromboelastography. Thromb Res 131: 352-356, 2013
37. Lewandowski AE, Liao WS, Stinson-Fisher CA, Kent JD, Jefferson LS: Effects of experimentally induced nephrosis on protein synthesis in rat liver. Am J Physiol 254: C634-C642, 1988
38. Jukkola A, Risteli J, Autio-Harmainen H, Risteli L: Effects of experimental nephrosis on basement-membrane components and enzymes of collagen biosynthesis in rat kidney. Biochem J 226: 243-250, 1985
39. Sidhu JS, Omiecinski CJ: Protein synthesis inhibitors exhibit a nonspecific effect on phenobarbital-inducible cytochome P450 gene expression in primary rat hepatocytes. J Biol Chem 273: 4769-4775, 1998
40. Downs SM: Protein synthesis inhibitors prevent both spontaneous and hormone-dependent maturation of isolated mouse oocytes. Mol Reprod Dev 27: 235-243, 1990
41. Coers W, Huitema S, van der Horst ML, Weening JJ: Puromycin aminonucleoside and adriamycin disturb cytoskeletal and extracellular matrix protein organization, but not protein synthesis of cultured glomerular epithelial cells. Exp Nephrol 2: 40-50, 1994
42. BlumRH, Carter SK: Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249-259, 1974
43. Duff OC, Ho KM,Maybury SM: In vitro thrombotic tendency of reactive thrombocytosis in critically ill patients: A prospective case-control study. Anaesth Intensive Care 40: 472-478, 2012
44. Furugohri T, Shiozaki Y, Muramatsu S, Honda Y, Matsumoto C, Isobe K, Sugiyama N: Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol 514: 35-42, 2005
45. Viswanatha GL, Mohamed R, Rajesh S, Sandeep RKS, Mohammed A, Anturlikar SD, Rangesh P, Patki PS: Anti-platelet and anti-thrombotic effects of a poly-ingredient formulation: In vitro and in vivo experimental evidences. Oman Med J 27: 1-5, 2012
46. Zhou J, May L, Liao P, Gross PL, Weitz JI: Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol 29: 863-869, 2009
47. Cooley BC: Murine models of thrombosis. Thromb Res 129[Suppl 2]: S62-S64, 2012
48. Diaz JA, Obi AT, Myers DD Jr., Wrobleski SK, Henke PK, Mackman N, Wakefield TW: Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 32: 556-562, 2012
49. Abildgaard U: Antithrombin-early prophecies and present challenges. Thromb Haemost 98: 97-104, 2007
50. Jøorgensen KA, Stoffersen E: Heparin like activity of albumin. Thromb Res 16: 569-574, 1979
51. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Kawachi H, Rakugi H, Imai E, Isaka Y: Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 24: 2354-2361, 2009
52. Broder A, Tobin JN, Putterman C: High antiphospholipid antibody levels are associated with statin use andmay reflect chronic endothelial damage in non-autoimmune thrombosis: Cross-sectional study. J Clin Pathol 65: 551-556, 2012
53. Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ: Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J MolMed (Berl) 84: 334-344, 2006
54. Schrem H, Klempnauer J, Borlak J: Liver-enriched transcription factors in liver function and development. Part I: The hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev 54: 129-158, 2002
55. Andersen RF, Palmfeldt J, Jespersen B, Gregersen N, Rittig S: Plasma and urine proteomic profiles in childhood idiopathic nephrotic syndrome. Proteomics Clin Appl 6: 382-393, 2012
56. Wang H, Madhusudhan T, He T, Hummel B, Schmidt S, Vinnikov IA, Shahzad K, KashifM,Muller-Krebs S, Schwenger V, Bierhaus A, Rudofsky G, Nawroth PP, Isermann B: Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: Protective effect of factor V Leiden in diabetic nephropathy. Blood 117: 5231-5242, 2011
57. Yamashita J, Nakajima K, Ohno Y, Kaneshiro Y, Matsuo T, Tanaka H, Kaneko K: Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats. Eur J Pharmacol 589: 239-244, 2008
58. Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS: Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: Current state of art and future perspectives. Blood 121: 1944-1950, 2013
59. Dargaud Y, Luddington R, Gray E, Lecompte T, Siegemund T, Baglin T, Hogwood J, Regnault V, Siegemund A, Negrier C: Standardisation of thrombin generation test-which reference plasma for TGT? An international multicentre study. Thromb Res 125: 353-356, 2010
60. Dargaud Y, Wolberg AS, Luddington R, Regnault V, Spronk H, Baglin T, Lecompte T, Ten Cate H, Negrier C: Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: An international multicentre study. Thromb Res 130: 929-934, 2012
61. Odegard OR, Lie M, Abildgaard U: Heparin cofactor activity measured with an amidolytic method. Thromb Res 6: 287-294, 1975